Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Antirheumatic Agents/*therapeutic use ; Arthritis, Rheumatoid/*drug therapy ; Arthritis, Rheumatoid/*epidemiology; Adult ; Cross-Sectional Studies ; Etanercept/therapeutic use ; Female ; Humans ; Jordan/epidemiology ; Lebanon/epidemiology ; Male ; Methotrexate/therapeutic use ; Middle Aged ; Odds Ratio ; Qatar/epidemiology ; Saudi Arabia/epidemiology ; United Arab Emirates/epidemiology
    • Abstract:
      Objectives: There is limited information on the epidemiology and treatment patterns of rheumatoid arthritis (RA) across the Arab region. We aim in this study to describe the demographic characteristics, clinical profile, and treatment patterns of patients of Arab ancestry with RA.
      Methods: This is a cross sectional study of 895 patients with established rheumatoid arthritis enrolled from five sites (Jordan, Lebanon, Qatar, Kingdom of Saudi Arabia (KSA), and United Arab Emirates). Demographic characteristics, clinical profile, and treatment patterns are compared between the five countries.
      Results: The majority of our patients are women, have an average disease duration of 10 years, are married and non-smokers, with completed secondary education. We report a high (>80%) ever-use of methotrexate (MTX) and steroids among our RA population, while the ever-use of disease modifying anti-rheumatic drugs (DMARDs) and TNF-inhibitors average around 67% and 33%, respectively. There are variations in RA treatment use between the five country sites. Highest utilization of steroids is identified in Jordan and KSA (p-value < 0.001), while the highest ever-use of TNF-inhibitors is reported in KSA (p-value < 0.001).
      Conclusion: Disparities in usage of RA treatments among Arab patients are noted across the five countries. National gross domestic product (GDP), as well as some other unique features in each country likely affect these. Developing treatment guidelines specific to this region could contribute in delivering standardized therapies to RA patients.
      Competing Interests: The authors have declared that no competing interests exist.
    • Comments:
      Erratum in: PLoS One. 2019 Mar 18;14(3):e0214258. (PMID: 30883600)
    • References:
      J Cancer Epidemiol. 2013;2013:916394. (PMID: 24282410)
      Ann Rheum Dis. 2014 Jan;73(1):62-8. (PMID: 24095940)
      Arthritis Res Ther. 2015 Nov 06;17:317. (PMID: 26546562)
      Arthritis Rheumatol. 2014 May;66(5):1101-10. (PMID: 24470106)
      Clin Ther. 2011 Jun;33(6):679-707. (PMID: 21704234)
      Best Pract Res Clin Rheumatol. 2012 Apr;26(2):251-61. (PMID: 22794097)
      Arthritis Res Ther. 2009;11(1):R7. (PMID: 19144159)
      Am J Med Genet A. 2014 Sep;164A(9):2212-6. (PMID: 24898111)
      Rheumatol Int. 2015 Apr;35(4):759-63. (PMID: 25315703)
      Ther Adv Musculoskelet Dis. 2014 Oct;6(5):169-84. (PMID: 25342996)
      Ann Rheum Dis. 2014 Jul;73(7):1316-22. (PMID: 24550173)
      Lancet. 2012 Dec 15;380(9859):2095-128. (PMID: 23245604)
      Rheumatology (Oxford). 2005 Nov;44(11):1394-8. (PMID: 16030083)
      Arthritis Rheum. 1988 Nov;31(11):1346-57. (PMID: 3190781)
      Curr Opin Rheumatol. 1999 Mar;11(2):98-103. (PMID: 10319211)
      Arthritis Rheumatol. 2017 May;69(5):976-985. (PMID: 28118524)
      Mod Rheumatol. 2008;18(3):228-39. (PMID: 18437286)
      Joint Bone Spine. 2011 Oct;78(5):484-7. (PMID: 21196130)
      Int J Rheum Dis. 2014 Jan;17(1):63-5. (PMID: 24472269)
      Rheumatol Int. 2014 Sep;34(9):1235-9. (PMID: 24633899)
      Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. (PMID: 26545825)
      Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796)
      Rheumatology (Oxford). 2000 Feb;39(2):122-32. (PMID: 10725061)
      Ann Rheum Dis. 2017 Jun;76(6):960-977. (PMID: 28264816)
      Int J Surg. 2015 Jan;13:71-75. (PMID: 25433249)
      Ann Rheum Dis. 2014 Jan;73(1):198-206. (PMID: 23467636)
      Clin Rheumatol. 2016 May;35(5):1153-9. (PMID: 26670453)
      Arthritis Care Res (Hoboken). 2014 Jul;66(7):980-9. (PMID: 24339352)
      Int J Rheum Dis. 2015 Mar;18(3):268-75. (PMID: 24620997)
      Rheumatology (Oxford). 2008 Jul;47(7):1061-4. (PMID: 18499716)
      Rheumatol Int. 2017 Sep;37(9):1551-1557. (PMID: 28455559)
      Clin Rheumatol. 2008 Jun;27(6):739-42. (PMID: 17973153)
      Ann Rheum Dis. 2013 Aug;72(8):1315-20. (PMID: 22945499)
      Autoimmun Rev. 2005 Mar;4(3):130-6. (PMID: 15823498)
      Ann Rheum Dis. 2016 Mar;75(3):540-6. (PMID: 25630346)
      QJM. 1999 Oct;92(10):551-63. (PMID: 10627876)
      Best Pract Res Clin Rheumatol. 2003 Oct;17(5):717-27. (PMID: 12915154)
    • Accession Number:
      0 (Antirheumatic Agents)
      OP401G7OJC (Etanercept)
      YL5FZ2Y5U1 (Methotrexate)
    • Publication Date:
      Date Created: 20181220 Date Completed: 20190506 Latest Revision: 20200309
    • Publication Date:
      20240105
    • Accession Number:
      PMC6300286
    • Accession Number:
      10.1371/journal.pone.0208240
    • Accession Number:
      30566451